Canada· CA-DIN-02279479
APIDRA
A insulin glulisine product containing insulin glulisine (recombinant dna origin), registered in Canada by SANOFI-AVENTIS CANADA INC. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Insulin glulisine is registered in 14 of 19 countries.
Countries holding a registration under ATC A10AB06 (insulin glulisine), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Insulin glulisine · ATC A10AB06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- INSULIN GLULISINE (RECOMBINANT DNA ORIGIN)
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Country
- Canada (CA)
- ATC code
- A10AB06
- ATC class
- Insulin glulisine
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
434 interactions on record for insulin glulisine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin glulisine · interactions on record
434 records
- 15 severe
- 368 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin glulisine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAPIDRASanofi-Aventis Deutschland GmbH, Frankfurt am Main
- United KingdomApidra 100units/ml solution for injection 10ml vialsSanofi
- SpainAPIDRA 100 UNIDADES/ml OPTICLIK SOLUCION INYECTABLE EN CARTUCHOSanofi-Aventis Deutschland Gmbh
- FinlandApidraSanofi-Aventis Deutschland GmbH
- SwitzerlandApidra
- IcelandApidraSanofi-Aventis Deutschland GmbH
- ItalyAPIDRA*1 flaconcino SC 10 ml 100 U/mlSANOFI AVENTIS DEUTSCHL.GMBH
- Japanインスリングルリジン（遺伝子組換え）サノフィ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Apidra, Apidra Solostar
- Liechtenstein · Apidra, Apidra Solostar
- Norway · Apidra, Apidra Solostar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3ed390f5-fb7f-452c-a2ef-8f2a83234e9b GET /v1/drugs/3ed390f5-fb7f-452c-a2ef-8f2a83234e9b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02279479",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10AB06",
"schedule": [
"Schedule D"
],
"drug_code": "76507",
"strengths": [
"100 UNIT"
],
"ahfs_class": null,
"substances": [
"INSULIN GLULISINE (RECOMBINANT DNA ORIGIN)"
],
"product_categorization": null
}See everything about insulin glulisine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.